Protagonist Therapeutics Inc (DE:PGF)
NASDAQ:PGF
PGF Stock Chart & Stats
€75.00
-€1.00(-2.69%)
At close: 4:00 PM EST
€75.00
-€1.00(-2.69%)
Day’s Range― - ―
52-Week Range€42.20 - €81.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€5.43B
Enterprise Value€6.22B
Total Cash (Recent Filing)€547.79M
Total Debt (Recent Filing)€9.78M
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Jul 30, 2026EPS Estimate
2.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.80
Shares Outstanding64,311,370
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)9.03
Price to Sales (P/S)120.66
P/FCF Ratio99.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€101.53Price Target Upside35.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)3.46
Revenue Forecast (FY)€432.63M
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetVery low leverage (TTM debt-to-equity ~0.015) and substantial equity ($655.5M) create durable funding flexibility. This conservative capital structure supports ongoing R&D spending, allows the company to absorb operating swings, and reduces near-term refinancing risk.
High Gross Margin And Revenue AccelerationMaterial revenue acceleration (+60.95% TTM) coupled with an unusually high gross margin (~99%) indicates scalable, high-margin economics typical of licensing or platform-based biotech. If managed, these structural margins support long-run profitability as development programs advance.
Specialized Peptide Therapeutics PlatformA focused peptide-engineering platform targeting inflammatory and immune diseases provides a durable competitive angle. Specialization can drive differentiated candidates, stronger partnership appeal, and repeatable licensing opportunities across indications as clinical programs progress.
Bears Say
Negative Operating And Free Cash FlowSustained negative operating cash flow (-$116.6M TTM) and free cash flow (-$116.3M) represent structural cash burn. Continued deficits increase reliance on the balance sheet or external financing to fund R&D and trials, raising dilution or covenant risks if losses persist.
Deep, Volatile Losses And Weak ReturnsSevere negative margins (EBIT ~-183%, net ~-155%) and negative ROE (~-17.8%) reflect volatile profitability. This reduces earnings quality and makes forecasting cash needs harder, weakening internal capacity to sustain multi-year development without partner funding or new capital.
Revenue Reliant On Collaborations/licensingDependence on upfronts, milestones and royalties ties revenue to partner decisions and clinical/regulatory outcomes. Until an approved product generates sales, revenue predictability is limited and contingent, increasing execution risk and sensitivity to partner timelines and negotiation outcomes.
Protagonist Therapeutics News
PGF FAQ
What was Protagonist Therapeutics Inc’s price range in the past 12 months?
Protagonist Therapeutics Inc lowest stock price was €42.20 and its highest was €81.00 in the past 12 months.
What is Protagonist Therapeutics Inc’s market cap?
Protagonist Therapeutics Inc’s market cap is €5.43B.
When is Protagonist Therapeutics Inc’s upcoming earnings report date?
Protagonist Therapeutics Inc’s upcoming earnings report date is Jul 30, 2026 which is in 52 days.
How were Protagonist Therapeutics Inc’s earnings last quarter?
Protagonist Therapeutics Inc released its earnings results on May 05, 2026. The company reported €0.043 earnings per share for the quarter, beating the consensus estimate of -€0.431 by €0.474.
Is Protagonist Therapeutics Inc overvalued?
According to Wall Street analysts Protagonist Therapeutics Inc’s price is currently Undervalued.
Does Protagonist Therapeutics Inc pay dividends?
Protagonist Therapeutics Inc does not currently pay dividends.
What is Protagonist Therapeutics Inc’s EPS estimate?
Protagonist Therapeutics Inc’s EPS estimate is 2.09.
How many shares outstanding does Protagonist Therapeutics Inc have?
Protagonist Therapeutics Inc has 64,311,370 shares outstanding.
What happened to Protagonist Therapeutics Inc’s price movement after its last earnings report?
Protagonist Therapeutics Inc reported an EPS of €0.043 in its last earnings report, beating expectations of -€0.431. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Protagonist Therapeutics Inc?
Currently, no hedge funds are holding shares in DE:PGF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Protagonist Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€101.53 (35.38% Upside)
€101.53 (35.38% Upside)
Blogger Sentiment
Bullish
DE:PGF Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €22.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
80.93%
12-Months-Change
Fundamentals
Return on Equity
-17.76%
Trailing 12-Months
Asset Growth
-6.02%
Trailing 12-Months
Company Description
Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
PGF Stock 12 Month Forecast
Average Price Target
€101.53
▲(35.38% Upside)
Technical Analysis
ADMA Biologics
―
Zai Lab
―
―
Mirum Pharmaceuticals
―
Ascentage Pharma Group International Unsponsored ADR
―
Options Prices
Currently, No data available
---